Avelas Biosciences to Present at 2018 Cantor Global Healthcare Conference
September 26, 2018
News
Avelas Biosciences Initiates Period 2 of Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
August 2, 2018
Avelas Biosciences to Present at JMP Securities Annual Life Sciences Conference
June 14, 2018
Avelas Biosciences to Present at Needham & Company 17th Annual Healthcare Conference
March 21, 2018
Avelas Biosciences to Present at Oppenheimer 28th Annual Healthcare Conference
March 13, 2018
Avelas Biosciences Completes Period 1 Patient Enrollment in Phase 2 Study of AVB-620 in Women with Primary, Nonrecurrent Breast Cancer Undergoing Surgery
January 4, 2018
Avelas Biosciences Broadens Management Team with Key Executive Additions
January 3, 2018
Avelas Biosciences to Present at Piper Jaffray Healthcare Conference
November 21, 2017
Newly Published Data Supports Avelas Biosciences’ Investigational Ratiometric Activatable Fluorescent Peptide AVB-620 in Intraoperative Tumor Detection
September 26, 2017
Avelas Biosciences’ AVB-620 Shows Sensitive In Vivo Visualization of Breast Cancer in Journal Publication
September 14, 2017